1. Assessing response of therapy for acute and chronic graft-versus-host disease. Issue 1 (February 2013) Authors: Goldberg, Jenna D; Giralt, Sergio Journal: Expert review of hematology Issue: Volume 6:Issue 1(2013) Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessing response of therapy for acute and chronic graft-versus-host disease. Issue 1 (February 2013) Authors: Goldberg, Jenna D; Giralt, Sergio Journal: Expert review of hematology Issue: Volume 6:Issue 1(2013) Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Issue 10297 (24th July 2021) Authors: Berdeja, Jesus G; Madduri, Deepu; Usmani, Saad Z; Jakubowiak, Andrzej; Agha, Mounzer; Cohen, Adam D; Stewart, A Keith; Hari, Parameswaran; Htut, Myo; Lesokhin, Alexander; Deol, Abhinav; Munshi, Nikhil C; O'Donnell, Elizabeth; Avigan, David; Singh, Indrajeet; Zudaire, Enrique; Yeh, Tzu-Min; Allred... Journal: Lancet Issue: Volume 398:Issue 10297(2021) Page Start: 314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Issue 12 (December 2022) Authors: Martin, Thomas; Lin, Yi; Agha, Mounzer; Cohen, Adam D; Htut, Myo; Stewart, A Keith; Hari, Parameswaran; Berdeja, Jesus G; Usmani, Saad Z; Yeh, Tzu-Min; Olyslager, Yunsi; Goldberg, Jenna D; Schecter, Jordan M; Madduri, Deepu; Jackson, Carolyn C; Deraedt, William; Gries, Katharine S; Fastenau, John... Journal: Lancet Issue: Volume 9:Issue 12(2022) Page Start: e897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Issue 10020 (20th February 2016) Authors: Dreyling, Martin; Jurczak, Wojciech; Jerkeman, Mats; Silva, Rodrigo Santucci; Rusconi, Chiara; Trneny, Marek; Offner, Fritz; Caballero, Dolores; Joao, Cristina; Witzens-Harig, Mathias; Hess, Georg; Bence-Bruckler, Isabelle; Cho, Seok-Goo; Bothos, John; Goldberg, Jenna D; Enny, Christopher; Traina... Journal: Lancet Issue: Volume 387:Issue 10020(2016) Page Start: 770 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Issue 10301 (21st August 2021) Authors: Usmani, Saad Z; Garfall, Alfred L; van de Donk, Niels W C J; Nahi, Hareth; San-Miguel, Jesus F; Oriol, Albert; Rosinol, Laura; Chari, Ajai; Bhutani, Manisha; Karlin, Lionel; Benboubker, Lotfi; Pei, Lixia; Verona, Raluca; Girgis, Suzette; Stephenson, Tara; Elsayed, Yusri; Infante, Jeffrey; Goldber... Journal: Lancet Issue: Volume 398:Issue 10301(2021) Page Start: 665 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗